In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT), with a price target of $178. The company’s shares opened today at $151.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 30.0% and a 52.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $200.21 average price target, representing a 32.6% upside. In a report issued on September 21, H.C. Wainwright also maintained a Buy rating on the stock with a $267 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $46.07. Currently, Sarepta Therapeutics has an average volume of 1M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
